MBS2320 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	2

46. 悪性関節リウマチ

---

臨床試験数 : 4,325 /  薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03139136 (ClinicalTrials.gov)	May 30, 2017	26/4/2017	Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis	A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate	Rheumatoid Arthritis	Drug: MBS2320;Drug: Placebo	Modern Biosciences plc	NULL	Completed	18 Years	75 Years	All	121	Phase 2	Georgia;Moldova, Republic of;Romania
2	NCT02480946 (ClinicalTrials.gov)	July 2015	16/6/2015	Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis	A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate	Arthritis, Rheumatoid	Drug: MBS2320;Drug: Placebo;Drug: Methotrexate	Modern Biosciences plc	Covance	Completed	18 Years	70 Years	All	105	Phase 1	United Kingdom